PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 31453368-11 2019 HCC recurred at 16.76/100py (95%CI: 10.75, 22.91) in the DAA-treated group vs. 20.04/100py (95%CI: 2.58, 45.21) after IFN. daa 57-60 interferon alpha 1 Homo sapiens 118-121 32128704-13 2020 However, patients with past experience of IFN-free DAA treatment and genotype 3, CKD stage 4 or 5, and advanced liver fibrosis should be more closely observed. daa 51-54 interferon alpha 1 Homo sapiens 42-45 30848363-4 2019 RESULTS: More than 60% of patients had a history of failure to achieve SVR with interferon (IFN)-free DAA therapy. daa 102-105 interferon alpha 1 Homo sapiens 92-95 30848363-6 2019 Multivariate analysis identified a history of failure with IFN-free DAA therapy and pretreatment HCV RNA levels as factors significantly associated with treatment failure. daa 68-71 interferon alpha 1 Homo sapiens 59-62 30848363-7 2019 Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. daa 63-66 interferon alpha 1 Homo sapiens 54-57 30848363-7 2019 Whereas the SVR rate in patients without a history of IFN-free DAA therapy was 91.7% (33 of 36 patients), it was only 30.9% (17 of 55 patients) among patients with a history of IFN-free DAA therapy. daa 186-189 interferon alpha 1 Homo sapiens 177-180 30848363-9 2019 CONCLUSIONS: Many patients treated with the DCV/ASV/BCV regimen have a history of a failure to achieve SVR with previous IFN-free DAA therapy. daa 130-133 interferon alpha 1 Homo sapiens 121-124 30848363-10 2019 SVR rate was not as high as that in pre-approval clinical trial of this regimen in IFN-free DAA-naive patients. daa 92-95 interferon alpha 1 Homo sapiens 83-86 30941326-2 2019 The aim of our study was to evaluate the efficacy of retreatment with genotype specific direct acting antivirals- (DAA-) based regimens in nonresponders to previous IFN-free therapy. daa 115-118 interferon alpha 1 Homo sapiens 165-168 32355687-0 2020 Risk management of hepatocellular carcinoma occurrence after hepatitis C virus eradication-from IFN based era to IFN-free DAA era. daa 122-125 interferon alpha 1 Homo sapiens 113-116 31123693-7 2019 The SVR rates increased over time in patients without a history of IFN-free DAA therapy. daa 76-79 interferon alpha 1 Homo sapiens 67-70 31123693-10 2019 Conclusions: Background characteristics of patients who undergo IFN-free DAA therapy are changing in Japan. daa 73-76 interferon alpha 1 Homo sapiens 64-67 31123693-11 2019 Patients without a history of IFN-free DAA therapy have high SVR rates. daa 39-42 interferon alpha 1 Homo sapiens 30-33 30443787-5 2019 IFN-free DAA treatment regimens provide a unique opportunity to assess the effect of HCV elimination on the immune system. daa 9-12 interferon alpha 1 Homo sapiens 0-3 30450781-12 2019 Our data demonstrate dynamic alterations in innate immune profiles during highly potent IFN-free DAA therapy. daa 97-100 interferon alpha 1 Homo sapiens 88-91 30956892-13 2018 Recognizing these findings are important in our understanding of the pathophysiology of the disease and management in the era of IFN-free DAA therapy. daa 138-141 interferon alpha 1 Homo sapiens 129-132 29704252-12 2018 Conclusion: An enhanced IFN signature is observed at baseline in liver and blood of patients who achieve SVR12 compared to those who experience a virological breakthrough; the findings suggest that innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy. daa 256-259 interferon alpha 1 Homo sapiens 24-27 29704252-12 2018 Conclusion: An enhanced IFN signature is observed at baseline in liver and blood of patients who achieve SVR12 compared to those who experience a virological breakthrough; the findings suggest that innate immunity may contribute to clearance of HCV during DAA therapy by preventing the emergence of resistance-associated substitutions that lead to viral breakthrough during DAA therapy. daa 374-377 interferon alpha 1 Homo sapiens 24-27 30026959-3 2018 In order to maximize the benefits of oral DAA therapy, we established an ambulatory care pharmacy practice, a model of integrated collaboration between physicians and pharmacists, for patients receiving IFN-free DAA therapy. daa 212-215 interferon alpha 1 Homo sapiens 203-206 29577581-5 2018 In total, 91 liver transplant recipients with recurrent HCV infection received IFN-free DAA treatment, 62 patients had IFN-based treatment failure, and 29 were treatment-naive, of whom 87 (96%) achieved SVR. daa 88-91 interferon alpha 1 Homo sapiens 79-82 30026959-11 2018 Results: Among the 401 study subjects, 386 patients completed the IFN-free DAA therapy. daa 75-78 interferon alpha 1 Homo sapiens 66-69 29920131-10 2018 We found that the SOCS1 expression in IFN and DAA-treated patient groups was 5.4 fold and 1.2 fold, respectively, high compared with the healthy controls (IFN versus healthy, P = 0.019 and DAA versus healthy, P = 0.91), whereas the SOCS3 expression in IFN and DAA-treated patient groups was 3.7 fold and 2 fold, respectively, high in comparison with the expression in healthy controls (IFN versus healthy, P = 0.025 and DAA versus healthy, P = 0.03). daa 46-49 interferon alpha 1 Homo sapiens 155-158 30001324-2 2018 Here, we posit a causal relationship between IFN-responsiveness and DAA treatment outcome. daa 68-71 interferon alpha 1 Homo sapiens 45-48 30001324-7 2018 An implication of the causal relationship is that failure of DAA-based treatments may be averted by adding IFN, a strategy of potential use in settings with limited access to DAAs. daa 61-64 interferon alpha 1 Homo sapiens 107-110 29205416-11 2018 Previously reported higher rates of HCC associated with DAA treatment may be explained by both the presence of relatively fewer baseline HCC risk factors in persons treated with IFN as well as selection bias, given that DAA regimens were used to treat persons at higher risk for developing HCC. daa 56-59 interferon alpha 1 Homo sapiens 178-181 29920131-10 2018 We found that the SOCS1 expression in IFN and DAA-treated patient groups was 5.4 fold and 1.2 fold, respectively, high compared with the healthy controls (IFN versus healthy, P = 0.019 and DAA versus healthy, P = 0.91), whereas the SOCS3 expression in IFN and DAA-treated patient groups was 3.7 fold and 2 fold, respectively, high in comparison with the expression in healthy controls (IFN versus healthy, P = 0.025 and DAA versus healthy, P = 0.03). daa 46-49 interferon alpha 1 Homo sapiens 155-158 29920131-10 2018 We found that the SOCS1 expression in IFN and DAA-treated patient groups was 5.4 fold and 1.2 fold, respectively, high compared with the healthy controls (IFN versus healthy, P = 0.019 and DAA versus healthy, P = 0.91), whereas the SOCS3 expression in IFN and DAA-treated patient groups was 3.7 fold and 2 fold, respectively, high in comparison with the expression in healthy controls (IFN versus healthy, P = 0.025 and DAA versus healthy, P = 0.03). daa 46-49 interferon alpha 1 Homo sapiens 155-158 29920131-10 2018 We found that the SOCS1 expression in IFN and DAA-treated patient groups was 5.4 fold and 1.2 fold, respectively, high compared with the healthy controls (IFN versus healthy, P = 0.019 and DAA versus healthy, P = 0.91), whereas the SOCS3 expression in IFN and DAA-treated patient groups was 3.7 fold and 2 fold, respectively, high in comparison with the expression in healthy controls (IFN versus healthy, P = 0.025 and DAA versus healthy, P = 0.03). daa 189-192 interferon alpha 1 Homo sapiens 38-41 29427484-4 2018 IFN-free DAA combinations can now cure HCV in more than 95% of patients with HCV infection after 8-12 weeks of treatment. daa 9-12 interferon alpha 1 Homo sapiens 0-4 29565742-9 2018 Our results suggest the over-expression of SOCS1 in PBMCs of IFN non-responders as compared to responders and DAA treated IFN non-responders. daa 110-113 interferon alpha 1 Homo sapiens 122-125 29659591-4 2018 This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR). daa 135-138 interferon alpha 1 Homo sapiens 126-129 29659591-4 2018 This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR). daa 135-138 interferon alpha 1 Homo sapiens 126-129 29659591-4 2018 This retrospective study analyzed 516 patients who underwent antiviral treatment for hepatitis C with either IFN (n = 148) or IFN-free DAA (n = 368) after curative HCC treatment; 78 IFN-treated patients and 347 IFN-free DAA-treated patients achieved sustained virological response (SVR). daa 135-138 interferon alpha 1 Homo sapiens 126-129 29327780-2 2018 However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. daa 61-64 interferon alpha 1 Homo sapiens 39-49 29327780-2 2018 However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking. daa 61-64 interferon alpha 1 Homo sapiens 51-54 29327780-3 2018 AIM: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. daa 94-97 interferon alpha 1 Homo sapiens 85-88 29430221-6 2017 He received immunosuppressive drugs and IFN-free DAA treatment after liver transplantation at 60 years of age, which led to disappearance of the symptoms of OLP. daa 49-52 interferon alpha 1 Homo sapiens 40-43 29399282-8 2018 Of the 119 patients who received IFN-free DAA (in different combinations), 102 achieved SVR and 9 failed (7/9 were on daclatasvir/asunaprevir and 2/9 on ledipasvir/sofosbuvir). daa 42-45 interferon alpha 1 Homo sapiens 33-36 29459562-6 2018 Owing to the high efficacy and safety of the DAA therapy, the number of patients referred to our hospital for anti-HCV therapy increased from 40.5 persons/year in the IFN phase to 80.3 persons/year in the DAA phase. daa 45-48 interferon alpha 1 Homo sapiens 167-170 28195337-5 2017 Also, studies with DAA-based therapies were more likely to report incidence of hepatitis due to HBV reactivation (12.2% in DAAs vs. 0% in IFN; P = 0.009 for heterogeneity between subgroups). daa 19-22 interferon alpha 1 Homo sapiens 138-141 28857900-2 2017 PATIENTS AND METHODS: A prospective cohort study was carried out in HCV monoinfected patients with advanced liver fibrosis or cirrhosis receiving interferon (IFN)-containing or IFN-free DAA therapy. daa 186-189 interferon alpha 1 Homo sapiens 177-180 28636655-12 2017 CONCLUSIONS: These results indicate that IFN-free regimens including newer DAA induce an early and marked decrease in circulating inflammatory biomarkers. daa 75-78 interferon alpha 1 Homo sapiens 41-44 24871445-5 2014 A number of promising new DAA regimens which are IFN-free are in phase 3 development and the first will likely be approved for use in the US in 2014. daa 26-29 interferon alpha 1 Homo sapiens 49-52 28617830-7 2017 After IFN-free DAAs, a rapid decrease of NKG2D at EOT correlated with early HCC emergence in the IFN-free DAA-treated patients, but not in patients treated with the IFN-combined regimen. daa 15-18 interferon alpha 1 Homo sapiens 6-9 27351356-2 2017 Using baseline data and viral kinetics, we developed a predictive algorithm to allocate to DAA patients who are not going to respond to peg-IFNalpha/RBV. daa 91-94 interferon alpha 1 Homo sapiens 140-148 28105744-9 2017 Interestingly, 57.1% of DAA IFN-free non-responders had a misclassified genotype, and 3/4 sofosbuvir breakthroughs showed the major-RAS-S282T, while RAS-L159F was frequently found in sofosbuvir relapsers (18.2%). daa 24-27 interferon alpha 1 Homo sapiens 28-31 28196130-5 2017 RESULTS: We observed an unexpected high prevalence of post-SVR inflammation, including patients who received novel IFN-free DAA-based therapies. daa 124-127 interferon alpha 1 Homo sapiens 115-118 27685337-9 2017 On treatment there was a statistically significant increase in total cholesterol for any IFN-free DAA regimen, which was maintained after end of therapy. daa 98-101 interferon alpha 1 Homo sapiens 89-92 27685337-13 2017 CONCLUSIONS: Suppressing and eliminating HCV with IFN-free DAA regimens increased cholesterol levels, but had no effect on triglycerides. daa 59-62 interferon alpha 1 Homo sapiens 50-53 26482547-3 2015 Therefore, IFN-free DAA formulations provide a unique opportunity to dissect the immunologic effect of HCV cure. daa 20-23 interferon alpha 1 Homo sapiens 11-14 25356568-7 2015 Economic barriers likely represents a major hurdle for the universal use of the novel IFN-free DAA regimens. daa 95-98 interferon alpha 1 Homo sapiens 86-89 25356568-8 2015 Local policies differ amongst health-care systems and reimbursement for DAA-based (ideally IFN-free) treatment regimens is often limited to certain HCV patient groups depending on individual need, expected efficacy, and available safety/efficacy data of the respective treatment regimen. daa 72-75 interferon alpha 1 Homo sapiens 91-94 28630501-9 2017 DAA treatment of HCV-infected PHHs reduced the expression of IFN-lambdas, including IFN-lambda4, and restored IFN-alpha responsiveness. daa 0-3 interferon alpha 1 Homo sapiens 110-119 28630501-11 2017 Moreover, the data clearly demonstrate that DAA therapy restores IFN-alpha responsiveness in HCV-infected cells. daa 44-47 interferon alpha 1 Homo sapiens 65-74 28249574-2 2017 The same observation has been made in Hepatitis C (HCV)-infected patients previously exposed to HBV and treated with interferon-free DAA treatments. daa 133-136 interferon alpha 1 Homo sapiens 117-127 28249574-14 2017 CONCLUSIONS: This case-report highlights the risk of HBV reactivation with interferon-free DAA treatment in HIV/HCV co-infected patients previously exposed to HBV and who have contraindications for treatment with nucleoside/nucleotide reverse transcriptase Inhibitors because of comorbid conditions. daa 91-94 interferon alpha 1 Homo sapiens 75-85 26950182-11 2016 Interferon-free DAA therapy is less likely to deteriorate sleep conditions in patients with CHC. daa 16-19 interferon alpha 1 Homo sapiens 0-10 26519873-16 2016 IFN-free DAA treatment represents a major improvement over prior IFN-based therapy. daa 9-12 interferon alpha 1 Homo sapiens 0-4 26519873-16 2016 IFN-free DAA treatment represents a major improvement over prior IFN-based therapy. daa 9-12 interferon alpha 1 Homo sapiens 0-3 26725891-2 2016 As a result of the exceedingly high cost of DAAs in many countries, IFN-free DAA regimens are mostly reserved to patients with advanced fibrosis or cirrhosis. daa 44-47 interferon alpha 1 Homo sapiens 68-72 24907428-5 2014 However, IFN-free DAA therapy is in its infancy, still to be proven and today is cost-prohibitive for the patient. daa 18-21 interferon alpha 1 Homo sapiens 9-12 24367041-3 2014 We report that in patients treated with the DAA sofosbuvir along with RBV, IFNL4-DeltaG is associated with slower early viral decay, due to slower loss of free virus (P = .039) and decreased drug efficacy (P = .048), suggesting functional relevance of IFN-lambda4 in IFN-alpha-free DAA therapies. daa 44-47 interferon alpha 1 Homo sapiens 267-276 21932410-12 2012 By chance, more patients treated with IFN/RBV had rs12979860 C/C-GT (up to 44%) than DAA-treated patients. daa 85-88 interferon alpha 1 Homo sapiens 38-41 24102413-5 2013 Therefore, IFN-free regimens are step for future therapies consisting of combinations of novel investigational DAA and host targeting agents. daa 111-114 interferon alpha 1 Homo sapiens 11-14 24330005-6 2014 IFN and ribavirin can still be indicated for patients with genotype 1a as a platform for combination with DAA. daa 106-109 interferon alpha 1 Homo sapiens 0-3 24330005-13 2014 When patients do not achieve SVR with first-generation DAA, low-dose IFN maintenance therapy is a treatment option until the next-generation therapy with pan-genotypic potency and high genetic barrier become available. daa 55-58 interferon alpha 1 Homo sapiens 69-72 25165553-10 2013 In addition, several studies demonstrate that IFN-free regimens with DAA combinations are able to cure a large number of either naive or treatment-experienced GT-1 patients. daa 69-72 interferon alpha 1 Homo sapiens 46-49 22300469-8 2012 However, new drugs may be associated with troublesome side effects and drugdrug interactions, and the ideal IFN-free DAA combination remains to be found. daa 117-120 interferon alpha 1 Homo sapiens 108-111 21897228-6 2011 Subsequent DAA agents appear to have improved tolerability and dosing schedules and open the door for interferon (IFN)-free DAA-based combination therapy. daa 11-14 interferon alpha 1 Homo sapiens 102-119 21897228-6 2011 Subsequent DAA agents appear to have improved tolerability and dosing schedules and open the door for interferon (IFN)-free DAA-based combination therapy. daa 124-127 interferon alpha 1 Homo sapiens 102-119